Left Bundle Branch Versus Minimized Ventricular Pacing in Patients With Sick Sinus Syndrome and Prolonged AV Interval

Recruiting now · Not applicable

Conditions studied: Sick Sinus Syndrome, Atrioventricular Nodal Dysfunction

In brief

The goal of this clinical trial is to compare two pacemaker strategies: Left Bundle Branch Area Pacing (LBBAP) and Minimized Ventricular Pacing (MVP) in patients requiring a permanent pacemaker for sick sinus syndrome and prolonged AV interval. It will also evaluate the safety and feasibility of the LBBAP method in these patients. The main questions it aims to answer is: \*Is LBBAP with physiological AV interval better than Minimized Ventricular Pacing? Researchers will compare the LBBAP group (aiming for conduction system capture with physiological AV intervals) to the MVP group (aiming to minimize ventricular pacing with prolonged AV intervals) to evaluate the optimal pacing strategy. Participants will: * Be randomly assigned to either the LBBAP group or the MVP group. * Undergo a pacemaker implantation procedure according to the specific criteria for their assigned group. * Visit the clinic for regular checkups to measure pacing function and ensure the device settings remain compliant with the study protocol.

Key facts

Study ID

NCT07314008

Run by

Asan Medical Center

People needed

440

Starts

2025-05-02

Expected to finish

2029-01-31

Last updated by the study team

2026-01-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >18 years old
• Sinus node dysfunction with symptoms
• Atrioventricular conduction delay (PR interval > 200ms)

You may not qualify if…

• Subject was unable to provide written informed consent or participate in long-term follow-up.
• Permanent atrial fibrillation
• Pre-existing cardiac implantable electronic device
• Persistent advanced atrioventricular conduction disturbance (2:1 block, Mobitz type II, or 3rd degree)
• Mechanical tricuspid valve
• Ventricular septal defect or scar
• Left ventricular ejection fraction < 35% who indicated cardiac resynchronization therapy
• Previous heart transplantation
• Pregnant and/or lactating women
• Life expectancy <2 year
• Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period

Where it is running

• Asan Medical Center — Seoul, Songpa-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.